An update on hereditary pancreatic cancer presented at the annual American Society of Clinical Oncology meeting covered genes and lifetime risk. The update emphasized that all pancreatic cancer patients should be offered genetic counseling and testing. Genetic test results may impact treatment, screening for other cancers and risk to family members. (11/26/19)
The National Comprehensive Cancer Network (NCCN) and The American Society of Clinical Oncologists (ASCO) recommend that all patients who are diagnosed with pancreatic cancer be offered genetic counseling and testing.
While numerous studies in the past have found no benefit (or an unclear benefit) to screening the general population for pancreatic cancer, recent research indicates that it is beneficial to screen people at higher risk.
International Cancer of the Pancreas Screening Consortium guidelines
American College of Gastroenterology guidelines:
NCT02000089: Cancer of the Pancreas Screening-5 Study (CAPS5). CAPS5 is a pancreatic cancer screening study for individuals at elevated risk for developing pancreas cancer.
NCT03693378. A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups. This study will validate and evaluate the performance of the IMMray PanCan-d test for pancreatic cancer diagnosis in comparison to standard of care imaging currently used in pancreatic cancer disease surveillance by the research sites’ institutions.
NCT03762590: The GENERATE (GENetic Education, Risk Assessment, and TEsting) Study. This study is for people who have a close relative with pancreatic cancer that was caused by an inherited mutation.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.